ESMO 2022 Conference Coverage
ESMO 2022 Updated Analysis of DESTINY-Gastric02 Trial: T-DXd in Western Patients With HER2+ Unresectable/Metastatic GC/GEJC Who Progressed on or After Trastuzumab-Containing Regimen
By
ESMO 2022 Conference Coverage
FEATURING
Geoffrey Ku
By
ESMO 2022 Conference Coverage
FEATURING
Geoffrey Ku
Login to view comments.
Click here to Login
GI